Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy

Akira Yokomizo, Ken Yamamoto, Naoko Kinukawa, Toshiyuki Tsunoda, Hirofumi Koga, Seiji Naito

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aim: Glutathione-S-transferase P1 (GSTP1) detoxifies a wide range of endogenous and exogenous carcinogens and anticancer agents such as cisplatin and doxorubicin. The aim of this study was to examine the association between GSTP1 polymorphism and both urothelial cancer susceptibility and adverse events of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy in Japanese urothelial cancer patients. Methods: This cohort consisted of 179 urothelial cancer patients and 225 healthy controls matched for age and sex. GSTP1 Ile105Val polymorphism was identified by direct sequencing methods. Furthermore, the association of GSTP1 polymorphism and adverse events of M-VAC chemotherapy was investigated. Results: A similar frequency of GSTP1 Ile105Val allele was observed in the urothelial cancer patients and in the control group. However, when the 46 patients who underwent systemic M-VAC chemotherapy were investigated, significantly more severe toxicity in leukocytopenia (P = 0.044, odds ratio +∞, 95% confidence interval 0.9203- +∞) and a prolonged duration of G-CSF administration (P = 0.013, odds ratio 8.625, 95% confidence interval 1.390-89.98) were observed in patients with the Val allele in comparison to those with the Ile allele. Conclusions: The GSTP1 Ile105Val polymorphism was not found to be significantly associated with urothelial cancer susceptibility but it may be associated with myelosuppressive adverse events in M-VAC chemotherapy. The 105Val might therefore be a useful marker for predicting myelosuppression in M-VAC chemotherapy.

Original languageEnglish
Pages (from-to)500-504
Number of pages5
JournalInternational Journal of Urology
Volume14
Issue number6
DOIs
Publication statusPublished - Jun 1 2007

Fingerprint

Vinblastine
Glutathione Transferase
Methotrexate
Doxorubicin
Cisplatin
Drug Therapy
Neoplasms
Alleles
Odds Ratio
Confidence Intervals
Leukopenia
Granulocyte Colony-Stimulating Factor
Carcinogens
Antineoplastic Agents
Control Groups

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy. / Yokomizo, Akira; Yamamoto, Ken; Kinukawa, Naoko; Tsunoda, Toshiyuki; Koga, Hirofumi; Naito, Seiji.

In: International Journal of Urology, Vol. 14, No. 6, 01.06.2007, p. 500-504.

Research output: Contribution to journalArticle

Yokomizo, Akira ; Yamamoto, Ken ; Kinukawa, Naoko ; Tsunoda, Toshiyuki ; Koga, Hirofumi ; Naito, Seiji. / Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy. In: International Journal of Urology. 2007 ; Vol. 14, No. 6. pp. 500-504.
@article{93ea5ca9ce404ae889cdd341fc0f8758,
title = "Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy",
abstract = "Aim: Glutathione-S-transferase P1 (GSTP1) detoxifies a wide range of endogenous and exogenous carcinogens and anticancer agents such as cisplatin and doxorubicin. The aim of this study was to examine the association between GSTP1 polymorphism and both urothelial cancer susceptibility and adverse events of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy in Japanese urothelial cancer patients. Methods: This cohort consisted of 179 urothelial cancer patients and 225 healthy controls matched for age and sex. GSTP1 Ile105Val polymorphism was identified by direct sequencing methods. Furthermore, the association of GSTP1 polymorphism and adverse events of M-VAC chemotherapy was investigated. Results: A similar frequency of GSTP1 Ile105Val allele was observed in the urothelial cancer patients and in the control group. However, when the 46 patients who underwent systemic M-VAC chemotherapy were investigated, significantly more severe toxicity in leukocytopenia (P = 0.044, odds ratio +∞, 95{\%} confidence interval 0.9203- +∞) and a prolonged duration of G-CSF administration (P = 0.013, odds ratio 8.625, 95{\%} confidence interval 1.390-89.98) were observed in patients with the Val allele in comparison to those with the Ile allele. Conclusions: The GSTP1 Ile105Val polymorphism was not found to be significantly associated with urothelial cancer susceptibility but it may be associated with myelosuppressive adverse events in M-VAC chemotherapy. The 105Val might therefore be a useful marker for predicting myelosuppression in M-VAC chemotherapy.",
author = "Akira Yokomizo and Ken Yamamoto and Naoko Kinukawa and Toshiyuki Tsunoda and Hirofumi Koga and Seiji Naito",
year = "2007",
month = "6",
day = "1",
doi = "10.1111/j.1442-2042.2007.01769.x",
language = "English",
volume = "14",
pages = "500--504",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy

AU - Yokomizo, Akira

AU - Yamamoto, Ken

AU - Kinukawa, Naoko

AU - Tsunoda, Toshiyuki

AU - Koga, Hirofumi

AU - Naito, Seiji

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Aim: Glutathione-S-transferase P1 (GSTP1) detoxifies a wide range of endogenous and exogenous carcinogens and anticancer agents such as cisplatin and doxorubicin. The aim of this study was to examine the association between GSTP1 polymorphism and both urothelial cancer susceptibility and adverse events of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy in Japanese urothelial cancer patients. Methods: This cohort consisted of 179 urothelial cancer patients and 225 healthy controls matched for age and sex. GSTP1 Ile105Val polymorphism was identified by direct sequencing methods. Furthermore, the association of GSTP1 polymorphism and adverse events of M-VAC chemotherapy was investigated. Results: A similar frequency of GSTP1 Ile105Val allele was observed in the urothelial cancer patients and in the control group. However, when the 46 patients who underwent systemic M-VAC chemotherapy were investigated, significantly more severe toxicity in leukocytopenia (P = 0.044, odds ratio +∞, 95% confidence interval 0.9203- +∞) and a prolonged duration of G-CSF administration (P = 0.013, odds ratio 8.625, 95% confidence interval 1.390-89.98) were observed in patients with the Val allele in comparison to those with the Ile allele. Conclusions: The GSTP1 Ile105Val polymorphism was not found to be significantly associated with urothelial cancer susceptibility but it may be associated with myelosuppressive adverse events in M-VAC chemotherapy. The 105Val might therefore be a useful marker for predicting myelosuppression in M-VAC chemotherapy.

AB - Aim: Glutathione-S-transferase P1 (GSTP1) detoxifies a wide range of endogenous and exogenous carcinogens and anticancer agents such as cisplatin and doxorubicin. The aim of this study was to examine the association between GSTP1 polymorphism and both urothelial cancer susceptibility and adverse events of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy in Japanese urothelial cancer patients. Methods: This cohort consisted of 179 urothelial cancer patients and 225 healthy controls matched for age and sex. GSTP1 Ile105Val polymorphism was identified by direct sequencing methods. Furthermore, the association of GSTP1 polymorphism and adverse events of M-VAC chemotherapy was investigated. Results: A similar frequency of GSTP1 Ile105Val allele was observed in the urothelial cancer patients and in the control group. However, when the 46 patients who underwent systemic M-VAC chemotherapy were investigated, significantly more severe toxicity in leukocytopenia (P = 0.044, odds ratio +∞, 95% confidence interval 0.9203- +∞) and a prolonged duration of G-CSF administration (P = 0.013, odds ratio 8.625, 95% confidence interval 1.390-89.98) were observed in patients with the Val allele in comparison to those with the Ile allele. Conclusions: The GSTP1 Ile105Val polymorphism was not found to be significantly associated with urothelial cancer susceptibility but it may be associated with myelosuppressive adverse events in M-VAC chemotherapy. The 105Val might therefore be a useful marker for predicting myelosuppression in M-VAC chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=34250878325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250878325&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2007.01769.x

DO - 10.1111/j.1442-2042.2007.01769.x

M3 - Article

C2 - 17593093

AN - SCOPUS:34250878325

VL - 14

SP - 500

EP - 504

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 6

ER -